Welcome to our dedicated page for Integrated Biopharma news (Ticker: INBP), a resource for investors and traders seeking the latest updates and insights on Integrated Biopharma stock.
Integrated BioPharma, Inc. reports operating results and business updates for an OTCQX-traded manufacturer and distributor of vitamins, nutritional supplements and herbal products. The company’s recurring news centers on quarterly and fiscal-year revenue, operating income or loss, net income per share and performance in its Contract Manufacturing Segment.
Company updates also discuss customer concentration among the segment’s largest customers, customer-base diversification, and activity tied to its core manufacturing, warehousing, distribution, marketing and sales operations.
Integrated BioPharma (OTCQX: INBP) announced that its wholly owned subsidiary, Manhattan Drug Company (MDC), appointed Michael G. Richtmyer as Head of Operations effective August 3, 2026. He brings more than 35 years of senior leadership in manufacturing, supply chain, quality and organizational transformation across pharmaceutical, nutraceutical, mineral, supplement, personal care and contract manufacturing sectors.
According to Integrated BioPharma, Richtmyer will oversee operational strategy and execution at MDC, focusing on manufacturing performance, supply chain reliability, quality systems, productivity and scalable growth. He previously served as President of Tishcon Corp. and earlier worked at the company from 1991 to 1999.
Integrated BioPharma (OTCQX: INBP) reported results for the quarter ended March 31, 2026. Quarterly revenue was $10.1M (down 27.3% vs. Q1 2025) and nine-month revenue was $34.1M (down 15.2% vs. prior year). The company recorded a quarterly operating loss of $1.1M and net loss of $0.8M. Gross profit for the quarter was negative $0.3M. Revenue from two largest contract-manufacturing customers represented approximately 90% of nine-month revenue in 2026.
Integrated BioPharma (OTCQX:INBP) reported results for the quarter ended December 31, 2025. Quarterly revenue was $11.3M, down 10.3% from $12.6M a year earlier, with an operating loss of $0.9M and net loss of $0.8M (basic EPS $(0.03)).
The company noted customer concentration: its two largest contract manufacturing customers represented approximately 89% of revenue for the six months ended December 31, 2025.
Integrated BioPharma (OTCQX: INBP) reported results for the quarter ended September 30, 2025. Revenue was $12.7 million, down 6.6% from $13.6 million a year earlier. Gross profit fell to $1.02 million from $1.37 million and operating income declined to $0.16 million from $0.49 million. Net income was $0.12 million, or $0.00 diluted per share, versus $0.26 million, or $0.01 diluted, in the prior-year quarter.
The company said its two largest Contract Manufacturing customers accounted for approximately 87% of revenue in Q3 2025 (85% in Q3 2024). Weighted average diluted shares were 31.42 million in Q3 2025. The company reiterated standard forward-looking cautionary language.
Integrated BioPharma (OTCQX:INBP) reported its financial results for Q4 and fiscal year 2025. The company achieved Q4 revenue of $14.2 million, up 11.8% year-over-year, and full-year revenue of $54.3 million, an 8.0% increase from FY2024.
For FY2025, INBP reported net income of $808,000 ($0.03 per share), compared to $112,000 in FY2024. However, Q4 2025 saw a net loss of $0.2 million (-$0.01 per share), versus net income of $0.3 million in Q4 2024. The company's Contract Manufacturing Segment showed strong customer concentration, with two largest customers representing 84% of total revenue in FY2025, down from 90% in FY2024.
Integrated BioPharma (OTCQX:INBP) reported financial results for Q4 2024, showing improved performance. Revenue increased by 9.6% to $12.6 million compared to $11.5 million in Q4 2023. The company turned around from an operating loss of $0.5 million in Q4 2023 to an operating income of $0.2 million in Q4 2024.
For the six-month period ended December 31, 2024, revenue grew 7.4% to $26.2 million, with operating income of $0.7 million compared to a loss of $0.5 million in the same period of 2023. Net income per share improved to $0.01 from a loss of $(0.02) in the comparable period. The company's two largest customers in the Contract Manufacturing Segment accounted for 82% of total revenue, down from 90% in the previous year, indicating successful customer base expansion.
Integrated BioPharma (INBP) reported financial results for Q3 2024, showing revenue of $13.6 million, a 5.4% increase from $12.9 million in Q3 2023. The company achieved operating income of $0.5 million, compared to a loss of $54,000 in the same period last year. Net income reached $0.3 million ($0.01 per share), improving from a net loss of $59,000 in Q3 2023. The company's two largest customers in Contract Manufacturing represented 85% of total revenue, down from 91% in 2023, reflecting progress in customer base diversification.
Integrated BioPharma (OTCQX:INBP) reported its financial results for the quarter and fiscal year ended June 30, 2024. Quarterly revenue was $12.7 million, a 2.3% decrease from $13.0 million in the same period in 2023. Quarterly operating income rose to $402,000 from $79,000. Fiscal year revenue was $50.3 million, down 0.7% from $50.7 million in 2023. Fiscal year operating income increased to $0.3 million from $0.1 million. Quarterly net income was $0.3 million or $0.01 per share, compared to $40,000 or $0.00 per share in the previous year. Fiscal year net income was $112,000 or $0.00 per share, versus a net loss of $34,000 or $0.00 per share last year. The company highlighted consistent revenue from its top two customers in the Contract Manufacturing Segment, representing 90% and 89% of total revenue in 2024 and 2023, respectively. The Co-CEOs expressed optimism about new prospects in contract manufacturing and warehousing and distribution.
Integrated BioPharma, Inc. reports its financial results for the quarter ended March 31, 2024. Revenue remained stable between 2023 and 2024 at $13.1 million. The Company experienced an operating income increase from $44,000 to $0.4 million in the same period. However, for the nine-month period, revenue decreased slightly by 0.3% to $37.6 million, with an operating loss of $0.2 million compared to operating income of $41,000 in the previous year. Net income per share rose to $0.01 from $0.00 in the quarter ended March 31, 2023, but the nine-month period saw a net loss of $0.2 million compared to $74,000 in the previous year. The Company aims to reduce reliance on two major customers in the future.